The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.

Patients under 55 years in the United Kingdom Medical Research Council Acute Myeloid Leukaemia 10 trial who entered complete remission were tissue typed (n = 1063). Four hundred and nineteen had a matched sibling donor and 644 had no match. When compared on a donor versus no donor basis the relapse...

Descrición completa

Detalles Bibliográficos
Main Authors:	Burnett, A, Wheatley, K, Goldstone, A, Stevens, R, Hann, I, Rees, J, Harrison, G
Formato:	Journal article
Idioma:	English
Publicado:	2002

Títulos similares

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party.
por: Webb, D, et al.
Publicado: (1999)

A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial.
por: Wheatley, K, et al.
Publicado: (1995)

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
por: Grimwade, D, et al.
Publicado: (1996)

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
por: Grimwade, D, et al.
Publicado: (1998)

Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial.
por: Watson, M, et al.
Publicado: (2004)

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial.
por: Watson, M, et al.
Publicado: (1999)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
por: Harrison, G, et al.
Publicado: (2000)

Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.
por: Chessells, J, et al.
Publicado: (2002)

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.
por: Grimwade, D, et al.
Publicado: (1999)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial
por: Harrison, G, et al.
Publicado: (2000)

Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials.
por: Peniket, A, et al.
Publicado: (1999)

Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience
por: Wheeler, K, et al.
Publicado: (1998)

EVI1 expression in acute myeloid leukaemia.
por: Langabeer, SE, et al.
Publicado: (2001)

Isolated Ocular Relapse of Acute Myeloid Leukaemia Post Allogeneic Stem Cell Transplant
por: M. H. Tong, et al.
Publicado: (2024-01-01)

Treatment of high risk leukaemia - Results of MRC childhood acute lymphoblastic leukaemia study MRC HR-1.
por: Kinsey, S, et al.
Publicado: (2002)

Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia.
por: Wheeler, K, et al.
Publicado: (1998)

Improved outcome of acute myeloid leukaemia in Down's syndrome.
por: Craze, J, et al.
Publicado: (1999)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
por: Hoyle, C, et al.
Publicado: (1989)

The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.
por: Kottaridis, P, et al.
Publicado: (2000)

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
por: Grimwade, D, et al.
Publicado: (2001)

Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
por: Hann, I, et al.
Publicado: (2000)

Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.
por: Grimwade, D, et al.
Publicado: (1999)

An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion.
por: Kottaridis, P, et al.
Publicado: (1999)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Iman Abou Dalle, et al.
Publicado: (2022-01-01)

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.
por: Secker-Walker, L, et al.
Publicado: (1997)

Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia
por: Roberto Bono, et al.
Publicado: (2024-04-01)

The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial
por: Burnett, AK, et al.
Publicado: (2018)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
por: Goh, Chermaine Yu Zhen
Publicado: (2021)

Three distinct subgroups of hypodiploidy in acute lymphoblastic leukemia in UK MRC trials.
por: Harrison, C, et al.
Publicado: (2003)

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
por: Gale, R, et al.
Publicado: (2018)

Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X.
por: Chessells, J, et al.
Publicado: (1992)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Giorgia Battipaglia, et al.
Publicado: (2022-03-01)

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A, et al.
Publicado: (2018)

Characterization of factors determining the kinetics of disease relapse after allogeneic Stem Cell Transplantation (allo-SCT) or chemotherapeutic consolidation for Acute Myeloid Leukaemia (AML) in First CR: A survey from HOVON-SAKK and the acute leukaemia working party of the EBMT
por: Craddock, C, et al.
Publicado: (2016)

Acute Myeloid Leukaemia (AML) Presenting as a Bilateral Pleural Effusion
por: Ranjan Agrawal
Publicado: (2013-01-01)

Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph plus) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993).
por: Goldstone, A, et al.
Publicado: (2001)

The role of molecular diagnosis and residual disease monitoring in APL: Results of the MRC ATRA trial.
por: Grimwade, D, et al.
Publicado: (1998)

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
por: Ganzel, C, et al.
Publicado: (2020)

Relationships between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council trials for acute myeloid leukemia AML 10 and 12.
por: Webb, D, et al.
Publicado: (2000)

Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia.
por: Webb, D, et al.
Publicado: (2001)